Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis

M Stampanoni Bassi, E Iezzi, GA Marfia, I Simonelli, A Musella, G Mandolesi, D Fresegna, P Pasqualetti, R Furlan, A Finardi, Giorgia Mataluni, Doriana Landi, L Gilio, D Centonze, F Buttari

Research output: Contribution to journalArticle

Abstract

Background: In the early phases of relapsing-remitting multiple sclerosis (RR-MS), a clear correlation between brain lesion load and clinical disability is often lacking, originating the so-called clinico-radiological paradox. Different factors may contribute to such discrepancy. In particular, synaptic plasticity may reduce the clinical expression of brain damage producing enduring enhancement of synaptic strength largely dependent on neurotrophin-induced protein synthesis. Cytokines released by the immune cells during acute inflammation can alter synaptic transmission and plasticity possibly influencing the clinical course of MS. In addition, immune cells may promote brain repair during the post-acute phases, by secreting different growth factors involved in neuronal and oligodendroglial cell survival. Platelet-derived growth factor (PDGF) is a neurotrophic factor that could be particularly involved in clinical recovery. Indeed, PDGF promotes long-term potentiation of synaptic activity in vitro and in MS and could therefore represent a key factor improving the clinical compensation of new brain lesions. The aim of the present study is to explore whether cerebrospinal fluid (CSF) PDGF concentrations at the time of diagnosis may influence the clinical course of RR-MS. Methods: At the time of diagnosis, we measured in 100 consecutive early MS patients the CSF concentrations of PDGF, of the main pro- and anti-inflammatory cytokines, and of reliable markers of neuronal damage. Clinical and radiological parameters of disease activity were prospectively collected during follow-up. Results: CSF PDGF levels were positively correlated with prolonged relapse-free survival. Radiological markers of disease activity, biochemical markers of neuronal damage, and clinical parameters of disease progression were instead not influenced by PDGF concentrations. Higher CSF PDGF levels were associated with an anti-inflammatory milieu within the central nervous system. Conclusions: Our results suggest that PDGF could promote a more prolonged relapse-free period during the course of RR-MS, without influencing inflammation reactivation and inflammation-driven neuronal damage and likely enhancing adaptive plasticity. © 2018 The Author(s).
Original languageEnglish
Article number108
JournalJournal of Neuroinflammation
Volume15
Issue number1
DOIs
Publication statusPublished - 2018

Fingerprint

Platelet-Derived Growth Factor
Multiple Sclerosis
Recurrence
Relapsing-Remitting Multiple Sclerosis
Cerebrospinal Fluid
Neuronal Plasticity
Nerve Growth Factors
Brain
Inflammation
Anti-Inflammatory Agents
Cytokines
Long-Term Potentiation
Synaptic Transmission
Disease Progression
Cell Survival
Intercellular Signaling Peptides and Proteins
Central Nervous System
Biomarkers
Survival

Cite this

Stampanoni Bassi, M., Iezzi, E., Marfia, GA., Simonelli, I., Musella, A., Mandolesi, G., ... Buttari, F. (2018). Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis. Journal of Neuroinflammation, 15(1), [108]. https://doi.org/10.1186/s12974-018-1150-4

Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis. / Stampanoni Bassi, M; Iezzi, E; Marfia, GA; Simonelli, I; Musella, A; Mandolesi, G; Fresegna, D; Pasqualetti, P; Furlan, R; Finardi, A; Mataluni, Giorgia; Landi, Doriana; Gilio, L; Centonze, D; Buttari, F.

In: Journal of Neuroinflammation, Vol. 15, No. 1, 108, 2018.

Research output: Contribution to journalArticle

Stampanoni Bassi, M, Iezzi, E, Marfia, GA, Simonelli, I, Musella, A, Mandolesi, G, Fresegna, D, Pasqualetti, P, Furlan, R, Finardi, A, Mataluni, G, Landi, D, Gilio, L, Centonze, D & Buttari, F 2018, 'Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis', Journal of Neuroinflammation, vol. 15, no. 1, 108. https://doi.org/10.1186/s12974-018-1150-4
Stampanoni Bassi, M ; Iezzi, E ; Marfia, GA ; Simonelli, I ; Musella, A ; Mandolesi, G ; Fresegna, D ; Pasqualetti, P ; Furlan, R ; Finardi, A ; Mataluni, Giorgia ; Landi, Doriana ; Gilio, L ; Centonze, D ; Buttari, F. / Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis. In: Journal of Neuroinflammation. 2018 ; Vol. 15, No. 1.
@article{7225012f55814342b404d767c1fb8f6a,
title = "Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis",
abstract = "Background: In the early phases of relapsing-remitting multiple sclerosis (RR-MS), a clear correlation between brain lesion load and clinical disability is often lacking, originating the so-called clinico-radiological paradox. Different factors may contribute to such discrepancy. In particular, synaptic plasticity may reduce the clinical expression of brain damage producing enduring enhancement of synaptic strength largely dependent on neurotrophin-induced protein synthesis. Cytokines released by the immune cells during acute inflammation can alter synaptic transmission and plasticity possibly influencing the clinical course of MS. In addition, immune cells may promote brain repair during the post-acute phases, by secreting different growth factors involved in neuronal and oligodendroglial cell survival. Platelet-derived growth factor (PDGF) is a neurotrophic factor that could be particularly involved in clinical recovery. Indeed, PDGF promotes long-term potentiation of synaptic activity in vitro and in MS and could therefore represent a key factor improving the clinical compensation of new brain lesions. The aim of the present study is to explore whether cerebrospinal fluid (CSF) PDGF concentrations at the time of diagnosis may influence the clinical course of RR-MS. Methods: At the time of diagnosis, we measured in 100 consecutive early MS patients the CSF concentrations of PDGF, of the main pro- and anti-inflammatory cytokines, and of reliable markers of neuronal damage. Clinical and radiological parameters of disease activity were prospectively collected during follow-up. Results: CSF PDGF levels were positively correlated with prolonged relapse-free survival. Radiological markers of disease activity, biochemical markers of neuronal damage, and clinical parameters of disease progression were instead not influenced by PDGF concentrations. Higher CSF PDGF levels were associated with an anti-inflammatory milieu within the central nervous system. Conclusions: Our results suggest that PDGF could promote a more prolonged relapse-free period during the course of RR-MS, without influencing inflammation reactivation and inflammation-driven neuronal damage and likely enhancing adaptive plasticity. {\circledC} 2018 The Author(s).",
author = "{Stampanoni Bassi}, M and E Iezzi and GA Marfia and I Simonelli and A Musella and G Mandolesi and D Fresegna and P Pasqualetti and R Furlan and A Finardi and Giorgia Mataluni and Doriana Landi and L Gilio and D Centonze and F Buttari",
year = "2018",
doi = "10.1186/s12974-018-1150-4",
language = "English",
volume = "15",
journal = "Journal of Neuroinflammation",
issn = "1742-2094",
publisher = "NLM (Medline)",
number = "1",

}

TY - JOUR

T1 - Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis

AU - Stampanoni Bassi, M

AU - Iezzi, E

AU - Marfia, GA

AU - Simonelli, I

AU - Musella, A

AU - Mandolesi, G

AU - Fresegna, D

AU - Pasqualetti, P

AU - Furlan, R

AU - Finardi, A

AU - Mataluni, Giorgia

AU - Landi, Doriana

AU - Gilio, L

AU - Centonze, D

AU - Buttari, F

PY - 2018

Y1 - 2018

N2 - Background: In the early phases of relapsing-remitting multiple sclerosis (RR-MS), a clear correlation between brain lesion load and clinical disability is often lacking, originating the so-called clinico-radiological paradox. Different factors may contribute to such discrepancy. In particular, synaptic plasticity may reduce the clinical expression of brain damage producing enduring enhancement of synaptic strength largely dependent on neurotrophin-induced protein synthesis. Cytokines released by the immune cells during acute inflammation can alter synaptic transmission and plasticity possibly influencing the clinical course of MS. In addition, immune cells may promote brain repair during the post-acute phases, by secreting different growth factors involved in neuronal and oligodendroglial cell survival. Platelet-derived growth factor (PDGF) is a neurotrophic factor that could be particularly involved in clinical recovery. Indeed, PDGF promotes long-term potentiation of synaptic activity in vitro and in MS and could therefore represent a key factor improving the clinical compensation of new brain lesions. The aim of the present study is to explore whether cerebrospinal fluid (CSF) PDGF concentrations at the time of diagnosis may influence the clinical course of RR-MS. Methods: At the time of diagnosis, we measured in 100 consecutive early MS patients the CSF concentrations of PDGF, of the main pro- and anti-inflammatory cytokines, and of reliable markers of neuronal damage. Clinical and radiological parameters of disease activity were prospectively collected during follow-up. Results: CSF PDGF levels were positively correlated with prolonged relapse-free survival. Radiological markers of disease activity, biochemical markers of neuronal damage, and clinical parameters of disease progression were instead not influenced by PDGF concentrations. Higher CSF PDGF levels were associated with an anti-inflammatory milieu within the central nervous system. Conclusions: Our results suggest that PDGF could promote a more prolonged relapse-free period during the course of RR-MS, without influencing inflammation reactivation and inflammation-driven neuronal damage and likely enhancing adaptive plasticity. © 2018 The Author(s).

AB - Background: In the early phases of relapsing-remitting multiple sclerosis (RR-MS), a clear correlation between brain lesion load and clinical disability is often lacking, originating the so-called clinico-radiological paradox. Different factors may contribute to such discrepancy. In particular, synaptic plasticity may reduce the clinical expression of brain damage producing enduring enhancement of synaptic strength largely dependent on neurotrophin-induced protein synthesis. Cytokines released by the immune cells during acute inflammation can alter synaptic transmission and plasticity possibly influencing the clinical course of MS. In addition, immune cells may promote brain repair during the post-acute phases, by secreting different growth factors involved in neuronal and oligodendroglial cell survival. Platelet-derived growth factor (PDGF) is a neurotrophic factor that could be particularly involved in clinical recovery. Indeed, PDGF promotes long-term potentiation of synaptic activity in vitro and in MS and could therefore represent a key factor improving the clinical compensation of new brain lesions. The aim of the present study is to explore whether cerebrospinal fluid (CSF) PDGF concentrations at the time of diagnosis may influence the clinical course of RR-MS. Methods: At the time of diagnosis, we measured in 100 consecutive early MS patients the CSF concentrations of PDGF, of the main pro- and anti-inflammatory cytokines, and of reliable markers of neuronal damage. Clinical and radiological parameters of disease activity were prospectively collected during follow-up. Results: CSF PDGF levels were positively correlated with prolonged relapse-free survival. Radiological markers of disease activity, biochemical markers of neuronal damage, and clinical parameters of disease progression were instead not influenced by PDGF concentrations. Higher CSF PDGF levels were associated with an anti-inflammatory milieu within the central nervous system. Conclusions: Our results suggest that PDGF could promote a more prolonged relapse-free period during the course of RR-MS, without influencing inflammation reactivation and inflammation-driven neuronal damage and likely enhancing adaptive plasticity. © 2018 The Author(s).

U2 - 10.1186/s12974-018-1150-4

DO - 10.1186/s12974-018-1150-4

M3 - Article

VL - 15

JO - Journal of Neuroinflammation

JF - Journal of Neuroinflammation

SN - 1742-2094

IS - 1

M1 - 108

ER -